Cite

HARVARD Citation

    Kurmasheva, R. et al. (2017). Initial testing (stage 1) of tazemetostat (EPZ‐6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program. Pediatric blood & cancer. 64 (3), p. n/a. [Online]. 
  
Back to record